About Inactive phospholipase C-like protein 2
Inactive phospholipase C-like protein 2 (PLCL2) is a protein
from Homo sapiens identified by UniProt accession
Q9UPR0, 1127 residues long.
MolForge cross-references it against 0 known binders and
176 disease associations.
Target properties
| Protein name | Inactive phospholipase C-like protein 2 |
|---|
| UniProt accession | Q9UPR0 |
|---|
| Gene | PLCL2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1127 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (176)
Diseases linked to this target (Open Targets).
- mean corpuscular volume · score 0.50
- mean corpuscular hemoglobin · score 0.48
- erythrocyte count · score 0.48
- fetal genotype effect measurement · score 0.48
- protein measurement · score 0.48
- mean corpuscular hemoglobin concentration · score 0.47
- mean reticulocyte volume · score 0.47
- eosinophil count · score 0.46
- basophil count · score 0.45
- Red cell distribution width · score 0.45
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UPR0-F1 | alphafold | PREDICTED | 80.59 | — |
Amino-acid sequence (1127 residues)
MAECGRGGAA GGALPTSPGP ALGAKGALKA GVGEGGGGGG RLGHGRARYD SGGVSNGDCS LGVSGDEARA SPTRGPRGVA LAPTPSAVVC TLPRESKPGG LPRRSSIIKD GTKQKRERKK TVSFSSMPTE KKISSASDCI NSMVEGSELK KVRSNSRIYH RYFLLDADMQ SLRWEPSKKD SEKAKIDIKS IKEVRTGKNT DIFRSNGISD QISEDCAFSV IYGENYESLD LVANSADVAN IWVTGLRYLI SYGKHTLDML ESSQDNMRTS WVSQMFSEID VDNLGHITLC NAVQCIRNLN PGLKTSKIEL KFKELHKSKD KAGTEVTKEE FIEVFHELCT RPEIYFLLVQ FSSNKEFLDT KDLMMFLEAE QGVAHINEEI SLEIIHKYEP SKEGQEKGWL SIDGFTNYLM SPDCYIFDPE HKKVCQDMKQ PLSHYFINSS HNTYLIEDQF RGPSDITGYI RALKMGCRSV ELDVWDGPDN EPVIYTGHTM TSQIVFRSVI DIINKYAFFA SEYPLILCLE NHCSIKQQKV MVQHMKKLLG DKLYTTSPNV EESYLPSPDV LKGKILIKAK KLSSNCSGVE GDVTDEDEGA EMSQRMGKEN MEQPNNVPVK RFQLCKELSE LVSICKSVQF KEFQVSFQVQ KYWEVCSFNE VLASKYANEN PGDFVNYNKR FLARVFPSPM RIDSSNMNPQ DFWKCGCQIV AMNFQTPGLM MDLNIGWFRQ NGNCGYVLRP AIMREEVSFF SANTKDSVPG VSPQLLHIKI ISGQNFPKPK GSGAKGDVVD PYVYVEIHGI PADCAEQRTK TVHQNGDAPI FDESFEFQIN LPELAMVRFV VLDDDYIGDE FIGQYTIPFE CLQTGYRHVP LQSLTGEVLA HASLFVHVAI TNRRGGGKPH KRGLSVRKGK KSREYASLRT LWIKTVDEVF KNAQPPIRDA TDLRENMQNA VVSFKELCGL SSVANLMQCM LAVSPRFLGP DNTPLVVLNL SEQYPTMELQ GIVPEVLKKI VTTYDMMIQS LKALIENADA VYEKIVHCQK AAMEFHEHLH SIGTKEGLKE RKLQKAVESF TWNITILKGQ ADLLKYAKNE TLENLKQIHF AAVSCGLNKP GTENADVQKP RRSLEVIPEK ANDETGE
Explore Inactive phospholipase C-like protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets